• ArgusEye is a spin-off company from Linköping University, Sweden. The company’s scienBfic idea is based on extensive research into the combinaBon of nanoplasmonic detecBon and fiber opBcs for integrated biodetecBon
• The technology’s flexible design can be adapted for use across a variety of potenBal applicaBon areas, including conBnuous automaBzed bioprocessing (Industry 4.0)

Stockholm — Eir Ventures today announced the compleon of an investment in ArgusEye, a biotechnology company developing sensor soluons for real-me detecon of biological systems and processes.

Biological drugs, such as anbodies, hormones and pepde products, are rapidly changing the pharmaceucal industry and already account for about 40% of all new FDA approvals across most therapy areas. However, current biopharmaceucal manufacturing processes are complex and expensive, with several crical producon steps that require extensive tesng during both development and manufacturing. Oen, each step needs to be manually analysed and controlled offline. New soluons that enable inline monitoring of important process parameters would allow for beer use of resources, shorter lead mes, increased efficiency, and improved product quality.

ArgusEye’s pioneering sensor technology allows for label-free detecon of bioproducon analytes and can be adapted to specific needs by customized sensor chips for a variety of targets. Integrated sensors that can replace offline analyses will save precious me and reduce costs especially during process development. Furthermore, the technology can facilitate process intensificaon and connuous processing, with the potenal of lowering capital and operaonal expenses considerably.

Erik Marnsson, co-founder and CEO of ArgusEye and co-inventor of the ArgusEye Sensor System, commented “We are delighted to join forces with Eir Ventures and see their investment in ArgusEye as evidence of their confidence in the company’s technology. The financing will enable us to finalize development and iniate product launch, and to expand the team”.

Magnus Persson, Founding Partner at Eir Ventures, holds an MD and PhD from the Karolinska Instute, with broad entrepreneurial and execuve experience from private both private and public biotech companies. Among other things, he was a Partner of life science venture capital firm HealthCap (Stockholm) and Partner at The Column Group (San Francisco) and has had a role in dozens of investments and exits. He states “We are very impressed with the team behind ArgusEye and see potenal for substanal improvements in current biopharmaceucal producon processes by applying the company´s innovave sensor technology. We are delighted to join and support the company as it works towards bringing its promising technology to the market”.

About ArgusEye

ArgusEye AB is a start-up company from Linköping, Sweden, that provides sensor soluons for real-me detecon of biological systems and processes. The company’s patented sensor technology is the result of extensive academic research at Linköping University and is based on nanoplasmonic sensing combined with fiber opcs. By adding specific receptors, the company can offer flexible and sensive sensing systems for a variety of targets. hp:// arguseye.se/

About Eir Ventures

Eir Ventures is a life science focused venture fund, with a strong foundaon in the Nordic Biotech ecosystem, that will invest in companies at early stage, as well as more mature opportunies. The fund started its investment acvies in 2020 and seeks investment opportunies addressing significant unmet medical needs for new therapies, medical technology and digital health. Eir Ventures AB is led by a team of experienced life science investors, and backed by a strong investor syndicate including Saminvest, the European Investment Fund (EIF), Væksonden, Novo Holdings, private investors as well as Nordic universies. Eir Ventures is a registered alternave investment fund, under the Swedish Alternave Investment Funds Managers Act. hps://eirventures.eu/